Improving Endovascular Treatment Through Process Refinements (ANGEL-IMPROVE)

November 17, 2026 updated by: Beijing Tiantan Hospital

Implementing Multiple Process Refinements for Optimal Value in Endo-vascular Treatment: A Cluster Randomized Clinical Trial

This study aims to evaluate the effectiveness of a structured, multi-component intervention package-the TIPS system-in improving the workflow and outcomes of endovascular treatment (EVT) for acute ischemic stroke caused by large vessel occlusion (LVO) in China. Despite EVT being a guideline-recommended therapy, delays in workflow processes such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT) remain widespread, especially in developing countries. The TIPS intervention focuses on key structure-process-outcome (SPO) elements and includes training & discussion, indicator feedback, professional guidance, and a solutions toolkit, implemented through a PDSA (Plan-Do-Study-Act) cycle. This multicenter, cluster-randomized study will assess whether the TIPS intervention improves EVT process efficiency and patient functional outcomes (90-day mRS). The findings are expected to support quality improvement and promote equitable stroke care delivery across China.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study aims to evaluate the effectiveness of a structured, multi-component quality improvement intervention (the TIPS system) in enhancing the workflow and patient outcomes of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO) in China. Although EVT is the guideline-recommended treatment, real-world data from both developed and developing countries demonstrate persistent delays in key workflow intervals, such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT), which are associated with functional outcomes.

The TIPS system integrates four core components: Training & Discussion, Indicator Feedback, Professional Guidance, and a Solutions Toolkit. It follows the Plan-Do-Study-Act (PDSA) model for continuous quality improvement and is built on the structure-process-outcome (SPO) framework. The intervention involves structured training, real-time data monitoring using an electronic data capture (EDC) platform, a 24/7 expert consultation team, and smart workflow tools such as the iStroke system and GreenFast app to support process tracking and decision-making.

ANGEL-IMPROVE is a multicenter, prospective, open-label, cluster-randomized trial with blinded endpoint assessment. A total of 100 tertiary hospitals across China will be stratified and randomized to either the intervention or control group. The study will enroll approximately 1,400 adult patients (≥18 years) receiving EVT. Control group hospitals will continue standard care; intervention group hospitals will implement the TIPS program.

The primary outcome is door-to-puncture time (DTP), defined as the time from arrival at the emergency department to arterial puncture, with a target of less than 90 minutes. Secondary outcomes include puncture-to-reperfusion time (PRT, target <60 minutes), successful reperfusion defined as mTICI ≥2b, functional outcomes including the proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, full mRS distribution, NIHSS scores at 24 hours and 7 days or discharge, and EQ-5D scores at 90 days. Safety outcomes include serious intraoperative complications (such as vessel perforation, dissection, or embolism), symptomatic intracranial hemorrhage within 48 hours based on Heidelberg criteria, any intracranial hemorrhage within 48 hours, stroke-related mortality, all-cause mortality, and serious adverse events within 90 days according to ICH-GCP definitions.

Statistical analysis will follow the intention-to-treat principle using the Full Analysis Set (FAS); Per Protocol Set (PPS) will be used for sensitivity analysis, and Safety Analysis Set (SAS) for safety evaluation. Continuous variables will be summarized as mean ± SD or median (IQR), and categorical variables as counts and percentages; group comparisons will use standard parametric or nonparametric tests. The primary outcome will be analyzed using generalized linear mixed models (GLMM) accounting for hospital-level clustering, time effects, and patient-level covariates. Secondary outcomes will be analyzed using ordinal logistic regression or Wilcoxon test for ordered variables, linear mixed models for continuous variables, and GLMM for binary outcomes; time-to-event outcomes will use Kaplan-Meier and Cox models. Safety events will be descriptively summarized in the SAS, with group comparisons using chi-square or Fisher's exact tests. All tests will be two-sided with a significance level of P < 0.05.

This trial aims to develop a replicable, scalable model of EVT workflow optimization in low- and middle-income settings and promote more equitable access to high-quality stroke care in China.

Study Type

Interventional

Enrollment (Estimated)

2862

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Beijing, China
        • Recruiting
        • Beijing Tiantan Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100010
        • Recruiting
        • Beijing Tiantan Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Eligibility Criteria Inclusion Criteria for Participating Centers

  • Tertiary hospitals (county-level hospitals preferred)
  • Equipped with an emergency department and a neurology ward that admits stroke patients
  • Capable of performing intravenous thrombolysis and endovascular treatment for acute ischemic stroke
  • Availability of a 24/7 in-hospital stroke emergency response team
  • Site principal investigator (PI) is committed to promoting the study, and the stroke team is willing to follow the study protocol, including randomization and interventions

Inclusion Criteria for Patients

  • Age ≥ 18 years
  • Undergoing endovascular treatment for acute ischemic stroke
  • Admitted through the emergency department
  • Written informed consent obtained from the patient or legally authorized representative for participation and follow-up

Exclusion Criteria for Participating Centers

  • Specialty hospitals (e.g., oncology, obstetrics/gynecology, pediatrics)
  • Fewer than 50 EVT cases per year for acute ischemic stroke
  • Inability to comply with the study protocol
  • Participation in other stroke-related quality improvement programs or clinical trials

Exclusion Criteria for Patients

  • Life expectancy less than 3 months or presence of severe comorbidities
  • Refusal to provide informed consent or inability to complete follow-up due to lack of consent or data sharing restrictions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group

Participants in the intervention arm will receive the TIPS system, a structured quality improvement package designed to optimize EVT workflow. TIPS stands for Training & discussion, Indicator feedback, Professional guidance, and Solutions toolkit. The intervention includes team-based training, data-driven performance feedback, expert-led consultations, and workflow tools such as iStroke and GreenFast, implemented through iterative Plan-Do-Study-Act (PDSA) cycles. Real-time monitoring and data management are supported by an integrated electronic data capture (EDC) platform.

This intervention consists of a structured, multicomponent quality improvement program named TIPS, designed to optimize endovascular treatment (EVT) workflow in acute ischemic stroke. TIPS stands for Training & Discussion, Indicator Feedback, Professional Guidance, and Solutions Toolkit. The program includes standardized training sessions, real-time performance feedback via an electronic data capture (EDC) system, 24/7 expert consultation, and process management tools such as the iStroke platform and GreenFast pathway. The intervention is delivered at the hospital level and implemented using a Plan-Do-Study-Act (PDSA) cycle. It is distinct from other QI initiatives by its structured SPO-based design (Structure-Process-Outcome) and its integration of real-time data monitoring and expert-guided iterative feedback.

No Intervention: Control Group

Conventional Endovascular Treatment Process

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Door-to-Puncture Time (DTP)
Time Frame: Periprocedural (from hospital arrival to arterial puncture)

DTP is defined as the time interval (in minutes) between a patient's arrival at the hospital emergency department (i.e., crossing the emergency entrance threshold) and the initiation of arterial access (puncture) in the angiography suite. It serves as a key indicator of workflow efficiency in endovascular treatment (EVT) for acute ischemic stroke. Shorter DTP is strongly associated with improved clinical outcomes. The threshold for achieving process quality is set at <90 minutes, as recommended by international guidelines. Time is measured from hospital records and procedural logs.

Periprocedural (from hospital arrival to arterial puncture)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Puncture-to-Reperfusion Time (PRT)
Time Frame: Periprocedural

PRT is defined as the time interval between the start of arterial puncture and the achievement of successful reperfusion, as determined by digital subtraction angiography (DSA). It reflects intra-procedural efficiency during endovascular treatment (EVT). A PRT <60 minutes is considered a quality benchmark. Time is recorded from procedure start to documented final angiographic run.

Periprocedural
Successful Reperfusion (mTICI ≥2b)
Time Frame: Periprocedural

Successful reperfusion is defined as achieving a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or higher on the final digital subtraction angiogram after EVT. This indicates restoration of adequate blood flow to the downstream territory. The mTICI scale ranges from 0 (no perfusion) to 3 (full perfusion), with 2b representing ≥50% filling of the affected territory.

Periprocedural
Functional Independence (mRS 0-2 at 90 days)
Time Frame: 90 days

Functional independence is defined as a score of 0-2 on the modified Rankin Scale (mRS) at 90 days post-treatment. The mRS measures the degree of disability or dependence in daily activities, ranging from 0 (no symptoms) to 6 (death). A score of 0-2 indicates independence in most daily functions.

90 days
NIHSS Score at 24 Hours and 7 Days (or Discharge)
Time Frame: 24 hours and 7 days (or Discharge)

The National Institutes of Health Stroke Scale (NIHSS) is a standardized measure used to assess neurological impairment following stroke. It ranges from 0 (no deficit) to 42 (severe stroke). NIHSS will be recorded at 24 hours and again at 7 days or hospital discharge, whichever occurs first, to monitor early neurological recovery.

24 hours and 7 days (or Discharge)
EQ-5D Quality of Life Score at 90 Days
Time Frame: 90 days

EQ-5D is a standardized measure of health-related quality of life consisting of five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five levels of severity. Patients (or caregivers) will complete the EQ-5D questionnaire via structured follow-up interview at 90 days to assess overall health status.

90 days
All-cause mortality rate
Time Frame: 90 days

All-cause mortality rate at 90±14 days

90 days
Any type of intracranial hemorrhage
Time Frame: 36 hours

Any type of intracranial hemorrhage according to Heidelberg Classification.

36 hours
Symptomatic Intracranial Hemorrhage
Time Frame: 36 hours

Symptomatic Intracranial Hemorrhage according to Heidelberg Classification.

36 hours
Serious Intraoperative Complications
Time Frame: Periprocedural

Defined as major adverse events occurring during the endovascular procedure, including but not limited to vessel perforation, dissection, acute occlusion, device malfunction (e.g., breakage), or distal embolization. These events require clinical intervention, may lead to procedure termination, and are considered to have potential impact on patient prognosis.

Periprocedural

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 15, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KY2024-270-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.